Oral Fredrickson type IIb hyperlipoproteinaemia, Fredrickson type IV hyperlipoproteinaemia
Adult: As an alternative or adjunct in patients who have not responded adequately to other treatments (e.g. statins, fibrates): Usual dose: 250 mg bid or tid. Dose is individualised based on the patient's plasma triglyceride and cholesterol levels. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
250 mg once daily or bid.
Should be taken with food. Take w/ or after meals.
Chống chỉ định
Active peptic ulcer. Severe renal impairment (CrCl <30 mL/min). Pregnancy and lactation. Contraindications may vary among individual products (refer to specific product labelling for detailed information).
Patient with acute haemorrhage; heart failure. Management with dietary changes and other non-pharmacological treatments (e.g. exercise, weight reduction, smoking or alcohol cessation) should be attempted prior to initiating treatment. Hepatic and mild to moderate renal impairment.
Tác dụng không mong muốn
Significant: Pruritus, flushing, erythema, rash. Eye disorders: Eye irritation, dry eyes. Gastrointestinal disorders: Dyspepsia, upper abdominal pain, nausea, diarrhoea. General disorders and administration site conditions: Asthenia, malaise, feeling hot. Immune system disorders: Anaphylactoid reaction. Musculoskeletal and connective tissue disorders: Myalgia, arthralgia, myositis. Nervous system disorders: Headache. Respiratory, thoracic and mediastinal disorders: Bronchospasm. Skin and subcutaneous tissue disorders: Urticaria, angioedema. Vascular disorders: Vasodilation.
Chỉ số theo dõi
Monitor lipid profile, liver and kidney function at baseline and periodically during therapy.
May enhance the myopathic (rhabdomyolysis) effect of statins and fibrates.
Description: Acipimox lowers blood cholesterol by inhibiting the release of fatty acids from adipose tissue and reducing serum levels of VLDL and LDL with a subsequent overall lowering of triglyceride and cholesterol levels. Additionally, it increases HDL concentrations during treatment. Pharmacokinetics: Absorption: Rapidly and completely absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 2 hours. Metabolism: Not significantly metabolised. Excretion: Via urine (mainly unchanged). Elimination half-life: Approx 2 hours.